On June 21, the United States Court of Appeals for the Federal Circuit (CAFC) denied a petition for rehearing and rehearing en banc filed by Amgen Inc., Amgen Manufacturing, Limited, and Amgen USA, Inc. (Amgen) in their case against Sanofi, Aventisub LLC, FKA Aventis Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., and Sanofi-Aventis U.S. LLC (Sanofi). Judge Lourie was joined by Judges Prost and Hughes in a separate opinion on the denial of the petition for panel rehearing. A group of intellectual property professors; GlaxoSmithKline plc; and Biogen Inc., Bristol-Myers Squibb Company, Corning Incorporated, and Merck Sharp & Dohme Corp. filed amicus briefs.
Recent Posts
- Judges Seem Frustrated with Judicial Council Arguments in Newman v. Moore Case
- Federal Circuit Reverses PTAB Win for Apple, Finding Board Erred in Its Applicant-Admitted Prior Art Analysis
- IPWatchdog Masters Panelists Urge U.S. Government to Get Organized When It Comes to AI
- Fixing the PTAB: 10 Things the USPTO Can Do to Improve the PTAB | IPWatchdog Unleashed
- Fox Succeeds in Scrapping Machine Learning Claims at CAFC Under 101